Dose-staged Gamma Knife radiosurgery for meningiomas: A retrospective study in a single center.

Objective: This study aimed to study the efficiency and safety of a dose-staged Gamma Knife radiosurgery strategy for large meningiomas or meningiomas close to important nerve structures. Methods: This study evaluates the outcome of a prospectively accrued series of 71 consecutive patients with meningiomas treated with staged dose-fractionated Gamma Knife radiosurgery. The average peripheral doses for the first and second fractions were 9.0 ± 0.9 Gy (8-12 Gy) and 8.6 ± 0.7 Gy (range, 7-10 Gy), respectively. The interval between fractions was 6.1 ± 1.9 months (range, 3-12 months). The median follow-up time was 36 months (12-96 months). Results: During the follow-up period after the second fraction, 97.2% achieved tumor control in our series. A total of 2 patients exhibited local recurrence at 30 and 60 months after the second fraction, respectively. No treatment-related complications or new long-term neurological dysfunctions were reported. MRIs observed slightly or moderately increased peritumoral edema in six patients, but no specific neurological complaints are attributed to this finding. Conclusion: This study investigates the efficiency and safety of dose-staged Gamma Knife radiosurgery as an alternative option for meningiomas that were large in volume, adjacent to crucial structures, or in patients with contraindications to craniotomy.

A new classification and clinical results of Gamma Knife radiosurgery for cavernous sinus hemangiomas: a report of 53 cases.

BACKGROUND: Cavernous sinus hemangiomas (CaSHs) are rare vascular lesions in the cavernous sinus(CS). Gamma Knife radiosurgery (GKS) provides a treatment modality alternative to microsurgery. This study was conducted to describe a new classification of CaSHs based on their magnetic resonance (MR) imaging findings and determine the efficacy and safety of GKS in a large series of CaSH patients. METHODS: From April 2007 to November 2012, 53 patients harboring CaSHs were treated using Leksell Gamma Knife model C (before April 2012) or Perfexion (from May 2012 ) at the Gamma Knife Center of Huashan Hospital. Of the 53 patients, 15 with definitive histopathologic diagnoses after surgery, 38 were diagnosed based on their MR imaging findings. There were 15 male and 38 female patients with a mean age of 52 (range, 25-76) years old. The characteristics of MR images of CaSHs were their extremely high homogeneous intensity on T2-weighted and FLAIR images: as bright as cerebrospinal fluid signal. According to the relationship between the carotid line and their location, CaSHs were classified into three types: the intrasellar, parasellar and mixed type. The mean volume of the tumors was 13.2 ± 8.2 cm(3) (range, 1-41 cm(3)). A mean marginal dose of 13.3 Gy (range, 8-15 Gy) was directed to the 49%-64% isodose line (mean 53%). RESULTS: Of the 53 tumors, 6 (11%) were classified as intrasellar type. Eight (15%) were parasellar type and the other 39 cases(74%) mixed type. The mean radiological and clinical follow-up time of this study was 24 (range, 2-67 months) and 34 months (range, 2-73 months), respectively. The tumor control rate was 100%. The mean tumor volume reduction was 79.5% (range, 16.5%-100%) compared with the pre-GKS volume. Six months after GKS, MR imaging revealed an average of 60.2% tumor volume reduction (range, 16.5%-89.2%). Twenty-nine cases (55%) showed a >80% tumor volume decrease. Neurologically, only two of these patients showed clinical deterioration, and 33 patients demonstrated an obvious improvement in ocular or endocrine disorders. At last follow-up, there were no more complications related to GKS, and none of the tumors progressed. CONCLUSIONS: Our study showed that GKS is a useful and safe therapeutic method for CaSHs as both a primary and adjuvant treatment. The new classification of CaSHs may help predict their clinical course during tumor development and treatment response after GKS. Further studies with long-term follow-up and larger numbers of cases are necessary to optimize the treatment conditions and verify the benefit of this treatment.

[Gamma knife for elderly patients with large vestibular schwannomas: 11-year follow-up].

OBJECTIVE: To evaluate the effect of Leksell Gamma Knife (LGK) on elderly patients with large vestibular schwannomas (VS) and to summarize the indications for LGK in patients with large VS. METHODS: From July 1994 to July 2000, 50 elderly patients (age range: 60.0 - 81.0 years) with large VS were treated by LGK as primary treatment modality. The maximal tumor diameter ranged from 31.0 to 61.0 mm [mean, (36.0 +/- 6.1) mm] and mean tumor volume was (14.8 +/- 8.0) cm(3) (range, 7.5 - 54.0 cm(3)). The maximal dose irradiated to tumor ranged from 22.0 to 28.0 Gy [mean: (25.0 +/- 1.6) Gy] and the mean tumor marginal dose was (12.3 +/- 0.9) Gy (range, 9.5 - 14.0 Gy). The mean follow-up duration was (86 +/- 12) months (range: 68 - 138 months). RESULTS: Of the 50 patients with follow-up data, 4 were deceased and 46 survived. Two patients with giant VS died at 6 and 9 months post-LGK respectively because of tumor swelling. Another two patients died of stroke or heart attack at 3 years and 4 years after LGK respectively, but their tumors decreased in volume. Clinical response: hearing: 14 (28%) patients preserved useful hearing as pre-LGK; 32 patients had unchanged or deteriorated hearing. Facial palsy: two patients developed mild facial palsy at 4 and 8 months respectively, one of them recovered and another improved later. Seven patients developed hydrocephalus around 6 months post-LGK and had V-P shunt. Eighteen patients had deteriorated facial numbness because of tumor swelling, 15 of them improved 3 years later. Tumor response: in 46 surviving patients, 43 tumors decreased markedly in size, 2 tumors remained stable in volume, 1 tumor progressed at five years and had second LGK. In this series tumor control rate was 94% (47/50). CONCLUSION: LGK provides an effective treatment for some selected large VS (maximal diameter

[Gamma knife radiosurgery for large trigeminal schwannomas].

OBJECTIVE: To evaluate the role of gamma knife (GK) radiosurgery in controlling large trigeminal schwannoma. METHODS: The clinical data of 30 patients suffering from large trigeminal schwannoma with a maximum diameter of 39.0 mm (31.0 to 53.0 mm), who underwent GK radiosurgery, used as the primary treatment modality in 20 patients and used to cure the residuals of tumor after microsurgery in 10 patients, with the maximum irradiation dose to tumor of 25.8 Gy (20.0 to 33.0 Gy) and a tumor margin dose of 12.2 Gy (9.0 to 14.0 Gy), were analyzed respectively. RESULTS: The 30 patients had been followed up for 78 months (24 to 136 months). Twenty-nine of the 30 patients were alive, and one patient with malignant trigeminal schwannoma died of tumor progression 36 months after the GK radiosurgery. Neurological deficits were improved in 24 patients and 3 patients' condition remained stable. Two patients' symptoms worsened 5 and 30 months after the GK radiosurgery respectively because of tumor swelling and tumor cyst enlarging. Then these two patients underwent microsurgery and their tumors were subtotally removed. Disappearance of tumor occurred in 4 patients, a marked decrease in tumor volume was observed in 20 patients, three tumors kept unchanged or slightly regressed in volume, and 3 tumors, including that of the patient who died, progressed. The tumor-growth control rate was 90% (27/30). Two patients underwent craniotomy after GK radiosurgery and one of these 2 resected specimens underwent histopathological examination. The histopathological findings of this tumor resected 30 months after GK radiosurgery revealed that most of the tumor tissue necrosed and was full of microcysts, the residual tumor cells in peripheral areas underwent hyaline degeneration, and the nuclei showed pyknosis. CONCLUSION: GK may be a good alternative treatment for selective patients suffering from large trigeminal schwannoma with a maximum diameter

[Analysis of the results of gamma knife radiosurgery for hemangioblastomas of the brain and the factors related to the tumor recurrence].

OBJECTIVE: To assess the 5-year-result of leksell gamma knife (LGK) in controlling hemangioblastomas of the brain (HB) and to analyze the factors related to tumor recurrence or development of new tumors. METHODS: From November 1993 to September 2001, 35 patients, 28 males and 7 females, aged 36 (16 approximately 61), 18 with multiple tumors and 17 with solitary tumor, the number of tumors being 93 in total, were treated by LGK. Twenty-one patients with HBs were associated with von Hippel-Lindau disease (VHLD). The tumor size ranged 5 approximately 55 mm with a mean size of 13 mm. The mean maximum irradiation dose was 35.6 Gy (20.0 approximately 50.0 Gy) at tumor center and the mean minimum dose was 17.2 Gy (12.0 approximately 24.0 Gy) at tumor periphery. Fisher exact test, independent T test and Wilcoxon rank sum W test were used to analyze the results of LGK on solitary and multiple HBs, the recurrent time of the HBs, and the relation between minimum irradiation dose and tumor control. RESULTS: 35 patients had been followed for 24 - 114 months with a mean value of 66 months. 29 patients were alive and 6 died. Of the 29 patients 21 achieved satisfying tumor control, and 8 patients underwent open surgery because of tumor-associated cysts enlarging or development of new tumors after LGK. 21 patients had improvement or remained stable in neurological status. Of the 8 reopened patients, 2 had deteriorated symptoms and the other 6 remained neurologically stable. Of the 35 patients, 7 developed new tumor during the follow-up period, and 5 had second LGK. Tumor control: Of the 29 cases, solitary or multiple tumors in 23 patients decreased in volume or remained the same, although two developed new tumors. The result of LGK in controlling HBs showed no significant difference between the solitary and multiple HBs (P > 0.05), but the dose of long-term tumor control was significantly higher than that of uncontrolled tumors (W = 98, P < 0.01). The tumor control rate was 94% 1 year after; 85% 2 years after; 82% 3 years after; 79% 4 years after; and 71% 5 years after. For the patients with solitary tumor, the mean time of development of new tumor was 63 months, but for the patients with multiple HBs, the time was 25 months. There was a significant difference between the two groups (t = 3.987, P < 0.001). With margin dose of 18 Gy, histopathology showed that no tumor cell was found and there were coagulation necrosis, hyaline degeneration and fibrosis tissues in the tumor nodule 48 months after LGK. CONCLUSION: LGK is a good choice for small- or medium-sized, solid HB in long term, especially when tumor margin dose is 16 - 20 Gy. Although LGK can treat multiple tumors in one single treatment session, for HB in patients associated with VHLD, LGK faces the problem of tumor recurrence or development of new tumor.

[Gamma knife radiosurgery for trigeminal schwannomas].

OBJECTIVE: To evaluate the role of gamma knife (GK) in the treatment of trigeminal schwannomas. METHODS: From June 1994 to June 2000, 38 patients with trigeminal schwannoma treated with GK radiosurgery were reviewed. GK was the primary treatment modality in 30 cases and followed microsurgery in 8 cases. Of the 38 tumors, 12 had small cysts within the tumors, the rest were solid. The mean diameter of the 38 tumors was 32 mm (range: 16 approximately 48 mm) and the tumors ranged in volume from 2 to 33 cm(3) (with a mean mean volume of 9 cm(3)). The maximum dose irradiated to tumor was 20 to 33 Gy (mean: 26 Gy), the tumor margin dose ranged from 11 to 15 Gy (mean: 13 Gy). RESULTS: 35 patients had been followed for 26 to 98 months (mean: 65 months). 20 had been followed more than 60 months. Mild numbness or diplopia relieved completely in 12 patients after GK treatment. Improvement of neurological deficits was seen in 11, unchanged dysfunction or slightly worsening of trigeminal nerve deficits in 9. Three patients had mild worsened symptoms at different time because of tumor progression. Tumor growth control: tumor disappeared after GK treatment was observed in 5 cases from 18 to 36 months after, a marked decrease in volume was observed in 24 cases, unchange in 2 cases and increase in 3 cases at 5, 26, and 60 months after respectively. One patient with resolved symptom refused to have MRI examination for more than 6 years. Of the three increased tumors, one recurrent malignant schwannoma elapsed 26 months after GK treatment. The second was a small tumor and started to progress 5 years after, but after second GK treatment, the tumor decreased again. The third was large tumor and was subtotally removed through surgery because of tumor swelling 5 months after. At last follow-up, the residual tumor remained stable. The control rate of the 35 tumors was 91% (32/35). CONCLUSION: Small and middle-size trigeminal schwannomas are the best candidates for GK radiosurgery. The control dose is 13 to 14 Gy.

Stereotactic radiosurgery in the treatment of primary central nervous system lymphoma.

OBJECTIVE: To explore the therapeutic alternatives and evaluate the related clinical results of patients with primary central nervous system lymphoma (PCNSL) treated with gamma knife radiosurgery (GKS). METHODS: From January 1995 to December 2001, 44 patients suffering from PCNSL, who had undergone stereotactic biopsy or craniotomy, and who had received a confirmed diagnosis through pathological examination, were treated with GKS. All cases were followed up for 1 - 46 months with an average postoperative period of 27 months. The clinical materials, image features, treatment methods and results of follow-up, were retrospectively reviewed. RESULTS: The symptoms and signs of the patients were markedly improved within 1 - 3 weeks after GKS. The Kanofsky performance status was also improved from a preoperative average of 40% to a postoperative one of 90%. Thirty-eight patients (86.36%) were in complete remission (CR), the other six (13.63%) were in partial remission (PR). The local control rate reached 100%, and the median survival time was 26.5 months. The main side effect was brain edema, which can be treated with dexamethasone and mannitol. CONCLUSION: GKS is a safe and effective method in multimodality treatment of PCNSL. A stereotactic biopsy coupled with GKS is the first choice for diagnosis and treatment. Adjuvant chemotherapy or radiotherapy should then be given according to the patient's condition.

[Gamma knife radiosurgery for hemangioblastomas: clinical results and pathological findings].

OBJECTIVE: To retrospectively evaluate the effects of Gamma knife in the treatment of cerebral hemangioblastomas. METHODS: From 1993 to 1996, seventeen patients with 29 hemangioblastomas were treated with Gamma knife. The patients mean age was 35 years (range: 16 - 61 years). The mean tumor diameter was 16 mm (range: 6 - 55 mm). Thirteen patients had recurrent or residual hemangioblastomas. Four with primary hemangioblastomas were diagnosed using CT, MRI and DSA. The maximum dose to the tumors was 21.0 - 50.0 Gy, with mean dose of 33.7 Gy. The radiation dose to the periphery of tumors was 12.0 - 24.0 Gy, with mean dose of 17.6 Gy. RESULTS: All the patients had been followed up for 18 to 62 months, with mean 46 months. Five patients experienced clinical improvement and reduction in tumor volume, and 5 remained stable and tumor unchanged in volume during the follow-up period. Three patients died of tumor progression, surgery and cancer after treatment 18, 22, 25 months respectively. Four patients underwent surgery respectively at 3, 4, 29 and 48 months after gamma knife operation. The local control rate of the tumors at 1 year was 92%, 2 years 88%, 3 years 80% and 4 years 75%. Pathological findings in these patients showed varying degrees of small vessel thickening and occlusion together with degeneration, necrosis in the center of tumor and loss of tumor cells at periphery. CONCLUSIONS: Gamma knife is not adequately reliable for the control of hemangioblastoma cysts, it is an effective treatment of small or medium-size solid tumors, but long-term follow-up is needed. The recommended dose is 16 to 20 Gy.